Break the page

Typically, the esoteric inner workings of finance and the very public stakes of government spending are viewed as separate spheres.And bond trading is ordinarily a tidy arena driven by mechanical bets about where the economy and interest rates will be months or years from now.But those separations and that sense of order changed this year as a gargantuan, chaotic battle was waged by traders in the nearly $27 trillion Treasury bond market — the place where the U.S. government goes to borrow.In the summer and fall, many investors worried that federal deficits were rising so rapidly that the government would flood the market with Treasury debt that would be met with meager demand. They believed that deficits were a key source of inflation that would erode future returns on any U.S. bonds they...

Illumina, the leading producer of gene-sequencing machines, announced Sunday that it would sell Grail, a cancer test developer that it purchased for $7.1 billion in 2021.The move came two days after Illumina lost its case in a federal appeals court, which largely upheld a Federal Trade Commission ruling that Illumina should unwind its deal with Grail on antitrust grounds.The case was seen by antitrust experts as a test of regulators’ efforts to stop big companies from buying fledgling innovators.The deal had also faced a roadblock in Europe. In September 2022, the European Union said it would block the acquisition. Illumina, based in San Diego, previously stated publicly that if it was unsuccessful with appeals in either jurisdiction, it would divest the start-up.“We are committed to an ex...